Nuformix PLC appointed Christopher Blackwell as a nonexecutive director of the company.
Blackwell served as the CEO of Vectura Group PLC from February 2004 to June 2015, taking the company through its initial IPO to a valuation of over $1 billion, Nuformix said in a statement.
Cambridge, U.K.-based Nuformix uses cocrystal technology to improve small molecule drugs.
Blackwell will assist the company as it develops its NXP002 programme for the treatment of fibrosis.
